LY117018 (TFA)

LY117018 TFA, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 TFA exerts antiproliferative effects on breast cancer cell lines[1][2][3].

Product Specifications

CAS Number

[2390041-98-0]

UNSPSC

12352005

Target

Estrogen Receptor/ERR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ly117018-tfa.html

Purity

99.18

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC(F)(C(O)=O)F.O=C(C1=CC=C(C=C1)OCCN2CCCC2)C3=C(SC4=CC(O)=CC=C43)C5=CC=C(C=C5)O

Molecular Formula

C29H26F3NO6S

Molecular Weight

573.58

References & Citations

[1]Dinda S, et al. Effects of LY117018 (a SERM analog of raloxifene) on tumor suppressor proteins and proliferation of breast cancer cells.Horm Mol Biol Clin Investig. 2010 Aug 1;2 (1) :211-7.|[2]Baumann KH, et al. Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.Breast Cancer (Auckl) . 2009 Apr 7;3:23-34.|[3]Yu J, et al.Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway.Eur J Pharmacol. 2008 Jul 28;589 (1-3) :32-6.